利拉鲁肽对2型糖尿病患者血清炎症因子的影响

摘要

目的：观察利拉鲁肽对2型糖尿病患者血清白细胞介素－6（IL－6）、肿瘤坏死因子－α（ TNF－α）、高敏C反应蛋白（ hs－CRP）的影响。方法选择住院的2型糖尿病患者40例为糖尿病组，同时期健康体检者40例作为对照组。糖尿病组给予利拉鲁肽治疗24周。测对照组及糖尿病组治疗前、治疗第12周、第24周空腹血糖（ FBG ）、餐后2 h 血糖（2hPG）、空腹胰岛素（FINS）、糖化血红蛋白（HbA1c）、hs－CRP、IL－6及TNF－α，计算胰岛素抵抗指数（ HOMA－IR）。结果治疗前，糖尿病组FBG、2hPG、HbA1c、HOMA－IR、IL－6、TNF－α、hs－CRP均显著高于对照组（P＜0．01），FINS显著低于对照组（P＜0．01）。治疗后， FBG、2hPG、HOMA－IR、IL－6、TNF－α、hs－CRP均显著降低（P均＜0．01），HbA1c逐步降低（P均＜0．05），FINS显著升高（P＜0．01）。结论利拉鲁肽可通过抑制2型糖尿病患者体内炎症反应，预防糖尿病及其并发症发展。%Objective It is to observe the effects of liraglutide on serum interleukin-6(IL-6), tumor necrosis factor-α( TNF-α) and C-reactive protein ( CRP) levels in patients with type 2 diabetes mellitus( T2DM) .Methods Forty patients with T2DM were selected as T2DM group and subjects-matched healthy controls as control group.The T2DM group was given an injection of liraglutide once-daily for 24 weeks.The fasting plasma glucose ( FPG) and 2-hour postprandial plasma glu-cose (2hPG),fasting insulin(FINS), HbA1C, serum CRP, IL-6 and TNF-αlevels were measured while HOMA-IR was calculated before and 12 weeks, 24 weeks after the treatment.Results The FBG and 2hPG,HbA1C, HOMA-IR, serum CRP, IL-6, TNF-αlevels in T2DM patients were significantly higher while FINS levels lower than that in control group be-fore treatment(P<0.01).After the treatment,the FPG, 2hPG, HbA1C, HOMA-IR, CRP, IL6, TNF-αlevels in T2DM patients were significantly reduced while the FINS levels increased(P<0.01).Conclusion Liraglutide can inhibit the inflam-matory reaction in order to delay or prevent the development of the complication in patients with type 2 diabetes mellitus.